To determine the effectiveness of corticosteroids (CCSs) (oral, IM, IV or inhaled) in the treatment of adult patients with acute asthma.
The authors have clearly stated their research question and inclusion and exclusion criteria. The literature search appears thorough, however the authors do not mention the inclusion of unpublished data in the review and they have limited the search to English language publications. It is therefore possible that additional relevant studies may have been missed. The quality of the included studies was assessed and the authors have reported on how the articles were selected and how many of the reviewers were involved in the data selection but not the data extraction.
The data extraction is reported in tables and text. The statistical pooling was appropriate and there were tests for heterogeneity, the results of which were used to guide further subgroup and sensitivity analyses. The authors discuss some of the methodological and data limitations in the review including the possibility of publication bias or study selection bias and the small number of studies being pooled.
The authors' conclusions appear to follow from the results.
Implications of the review for practice and research
Practice: The authors stated that early response of the patient to beta-agonist therapy would determine whether waiting for the onset of action of CCSs would be of value. When the PEFR is < 40% of predicted and PEFR variation over baseline is < 60 L/minute, both measured at 30 minutes of therapy, then it is possible to wait for the onset of action of inhaled CCSs for 2 or 3 additional hours. If the PEFR remains < 40% after that time, these patients will require hospitalisation and parenteral CCS therapy, since improvement from discharge from the hospital takes 4 days.
